Senti Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $12.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising clinical data and safety profile of Senti Biosciences’ SENTI-202 therapy. The company recently reported encouraging results from its Phase 1 trial for relapsed/refractory acute myeloid leukemia (AML), where SENTI-202 demonstrated a favorable safety profile with no dose-limiting toxicities and a manageable adverse event profile.
The observed overall response rate and complete response rates, despite being from a small patient cohort, suggest potential efficacy of the therapy. The anticipation of further data at the upcoming ASH conference, which could provide additional insights into response rates, durability, and safety, supports the positive outlook. The innovative CAR-NK technology, which targets specific leukemic cells while sparing healthy cells, adds to the potential of SENTI-202 as a promising treatment option, justifying the Buy rating.
In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $12.00 price target.